Associations between diabetic retinopathy and plasma levels of high-sensitive C-reactive protein or von willebrand factor in long-term type 1 diabetic patients

Current Eye Research

Volumn 38, Issue 1, 2013, Pages 174-179

  Laursen, Jonas Vejvad Norskov ^a   Hoffmann, Stine Skovbo ^a   Green, Anders ^a   Nybo, Mads ^a   Sjolie, Anne Katrin ^a   Grauslund, Jakob ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Diabetic retinopathy; High sensitive C reactive protein; Inflammation; Type 1 diabetes; Von Willebrand factor

Indexed keywords

C REACTIVE PROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CROSS-SECTIONAL STUDY; DENMARK; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OPHTHALMOSCOPY; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DENMARK; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 84872044803     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2012.713153     Document Type: Article

References (25)

1. Grauslund J, Green A, Sjøie AK. Prevalence and 25 year incidence of proliferative retinopathy among Danish type 1 diabetic patients. Diabetologia 2009;52:1829-1835
2. Grauslund J, Green A, Sjøie AK. Blindness in a 25-year follow-up of a population-based cohort of Danish type 1 diabetic patients. Ophthalmology 2009;116:2170-2174
3. Klein R, Lee KE, Gangnon RE, Klein BE. The 25-year incidence of visual impairment in type 1 diabetes mellitus - The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 2010;117:63-70
4. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD. EURODIAB Prospective Complications Study Group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes - The EURODIAB Prospective Complications Study. Diabetologia 2005;48:370-378
5. Klein BE, Knudtson MD, Tsai MY, Klein R. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol 2009;127:1175-1182
6. Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNFalpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complicat 2008;22:309-316
7. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-1452
8. Nowak M, Wielkoszynski T, Marek B, Kos-Kudła B, Swietochowska E, Siemińska L et al. Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Clin Exp Med 2010;10:185-192
9. Izuora KE, Chase HP, Jackson WE, Coll JR, Osberg IM, Gottlieb PA et al. Inflammatory markers and diabetic retinopathy in type 1 diabetes. Diabetes Care 2005;28:714-715
10. Chan NN, Fuller JH, Rubens M, Colhoun HM. Von Willebrand factor in type 1 diabetes: Its production and coronary artery calcification. Med Sci Monit 2003;9:CR297-CR303
11. Stehouwer CD, Zellenrath P, Polak BC, Baarsma GS, Nauta JJ, Donker AJ et al. von Willebrand factor and early diabetic retinopathy: No evidence for a relationship in patients with type 1 (insulin-dependent) diabetes mellitus and normal urinary albumin excretion. Diabetologia 1992;35:555-559
12. Greaves M, Malia RG, Goodfellow K, Mattock M, Stevens LK, Stephenson JM et al. Fibrinogen and von Willebrand factor in IDDM: Relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: The EURODIAB IDDM Complications Study. Diabetologia 1997;40:698-705
13. Sjøie AK, Stephenson J, Aldington S, Kohner E, Janka H, Stevens L et al. Retinopathy and vision loss in insulindependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 1997;104:252-260
14. Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M et al. EURODIAB Prospective Complications Study. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 2001;24:284-289
15. Green A, Hauge M, Holm NV, Rasch LL. Epidemiological studies of diabetes mellitus in Denmark. II. A prevalence study based on insulin prescriptions. Diabetologia 1981;20:468-470
16. Sjie AK. Ocular complications in insulin treated diabetes mellitus. An epidemiological study. Acta Ophthalmol SUPPL 1985;172:1-77
17. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs - An extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991;98:786-806
18. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98:823-833
19. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005;54:1615-1625
20. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995;92:905-909
21. Hayaishi-Okano R, Yamasaki Y, Katakami N, Ohtoshi K, Gorogawa S, Kuroda A. Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care 2002;25:1432-1438
22. Colhoun HM, Schalkwijk C, Rubens MB, Stehouwer CD. C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification. Diabetes Care 2002;25:1813-1817
23. Shahbazi S, Lenting PJ, Fribourg C, Terraube V, Denis CV, Christophe OD. Characterization of the interaction between von Willebrand factor and osteoprotegerin. J Thromb Haemost 2007;5:1956-1962
24. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: A systematic literature review. Eur J Endocrinol 2008;159:603-608
25. Grauslund J, Rasmussen LM, Green A, Sjie AK. Does osteoprotegerin relate to micro- And macrovascular complications in long-Term type 1 diabetes? Scand J Clin Lab Invest 2010;70:188-193